Pre-existing inflammatory disease predicts cutaneous immunotherapy toxicity development: A multi-institutional cohort study

Guihong Wan,Nga Nguyen,Bonnie W. Leung, Hannah Rashdan,Kimberly Tang,Katie Roster,Michael R. Collier,Pearl O. Ugwu-Dike,Neel S. Raval,Nora A. Alexander,Ruple Jairath,Jordan Phillipps,Munachimso Amadife,Shijia Zhang,Alexander Gusev,Steven T. Chen,Kerry L. Reynolds,Nicole R. LeBoeuf,Shawn G. Kwatra,Yevgeniy R. Semenov

Journal of the American Academy of Dermatology（2024）

引用 0|浏览31

暂无评分

摘要

ICI recipients with cutaneous pIDs should have increased clinical monitoring due to their increased risk of cirAE development, severity, and earlier onset.

查看译文

关键词

autoimmunity,cutaneous adverse reactions,cutaneous immune-related adverse events,immunotherapy,immune checkpoint inhibitor,oncodermatology,pre-existing inflammatory disease

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要